H eat shock proteins ( hsps ), which are induced by cellular stress, are molecular chaperones that mediate the assembly and folding of other cytosolic proteins, thereby protecting cells from environmental damage. 1, 2 Certain hsps, such as members of the hsp70 and 90 families, chaperone small antigenic peptides to MHC molecules for efficient antigen presentation. 3 -5 They are highly immunogenic, 6 with their antigenicity being derived from the peptides they chaperone. 5 Hsp complexes may contribute to the progression of certain autoimmune diseases, and hence are being considered as targets for the development of novel therapeutics to combat inflammation. 7 Conversely, their immunostimulatory potential can be harnessed to generate antitumor immunity, where the hsps act as vehicles for the delivery of antigenic tumor peptides to the MHC class I (endogenous ) antigen presentation pathway. 8 An hsp preparation derived from a particular cell type potentially contains the peptide repertoire of that cell type. Treatment of animals with hsp70 -and hsp96 -peptide complexes, either derived directly from tumor cells 5, 9 or reconstituted by combining purified hsp70 and hsp96 with a variety of synthetic peptides in vitro, 10 elicits peptide-specific CTL responses and potent antitumor immunity. Antitumor immunity is specific for the cancer from which the hsps are isolated. Hence, hsps provide cancer therapy without the need to identify tumor-specific antigenic epitopes. Hsp70 isolated from a human melanoma was able to activate T cells recognizing melanoma differentiation antigens in an antigen-and HLA class I-dependent fashion. 11 Even when devoid of endogenous peptides, it able to induce IFN -release by antimelanoma T cells by an MHCindependent mechanism.
11 Hsp70 stimulates monocytes to produce TNF -, IL-1, and IL -6, suggesting that it has a dual role as a chaperone and cytokine. 12 A pilot clinical study using autologous cancer-derived hsp96 preparations to treat cancer patients apparently showed no signs of autoimmunity, and led to an expansion of the NK cell population. 9, 13 In another experimental approach, B16 melanoma cells were stably transfected with human hsp72 ex vivo.
14 Such cells, which constitutively expressed hsp72, exhibited increased levels of cell surface MHC class I antigens, and increased immunogenicity. When employed to vaccinate animals, they elicited an immune response capable of rejecting wild -type tumor cells. B16 clones stably transfected with hsp70 did not display increased MHC class I expression; nevertheless, when injected subcutaneously, they induced an infiltrate of T cells, macrophages, and dendritic cells ( DCs ) into the tumor, and a protective Th1 cytokine profile.
15
Hsp70 released from dying tumor cells appeared to be taken up directly into DCs, and may mediate the direct chaperoning of tumor antigens into DCs. Hsps have been fused to antigens, such as human papillomavirus type 16 E7, thereby increasing the potency of a naked DNA vaccine. 16 In yet another approach, reticulum cell sarcomas were successfully treated by intraperitoneal liposome -mediated gene transfer of mycobacterial hsp65. 17 To date, gene transfer of either mammalian or autologous hsps into tumors in situ has not been attempted.
In enhancing tumor antigen presentation, hsps facilitate signal 1 of the two -signal model for T-cell activation and proliferation. 18 However, secondary signals provided by triggering one of a number of T-cell accessory receptors -such as the cell adhesion molecules ( CAMs ) CD28, CD2, and the integrins LFA -1, HML -1, LPAM -1, VLA -4, -5, -6, whose ligands are expressed on professional antigen -presenting cellsare necessary to drive T-cell proliferation in response to antigen, and /or to prevent T-cell anergy. 18, 19 We have previously demonstrated that optimized gene transfer of B7.1 (ligand for CD28 ) and the xenogeneic (human ) CAMs VCAM-1, MAdCAM -1 (ligands for LPAM -1 and VLA -4), and ICAM -1 (ligand for LFA -1) into tumors in situ causes rapid and complete rejection of established mouse EL -4 tumors, and generates prolonged systemic antitumor immunity. 20 In each case, the immune response was mediated by CD8 + T cells and NK cells, accompanied by augmented tumor-specific cytolytic T cell ( CTL ) activity.
It is plausible that enhanced antitumor immunity could be achieved by simultaneously stimulating both signal 1 ( antigen presentation ) and signal 2 ( CAM -mediated costimulation ) required for optimal T-cell proliferation. Here we examine this hypothesis by determining whether hsp70 and B7.1 synergize to enhance antitumor immunity.
MATERIALS AND METHODS

Cell line
The EL -4 thymic lymphoma cell line of C57BL /6 origin ( H -2b ) was purchased from the American Type Culture Collection (Rockville, MD ). EL -4 cells were cultured at 378C, 5% CO 2 in DMEM medium ( Invitrogen New Zealand Ltd., Penrose, Auckland, New Zealand ), supplemented with 10% (vol/vol ) fetal calf serum, 50 U / mL penicillin / streptomycin, 2 mM L -glutamine, and 1 mM pyruvate.
Inoculation of mice with EL -4 cells to establish tumors
Male C57BL /6 mice, 6 -8 weeks old, were obtained from the Animal Resource Unit, School of Medicine and Health Science, University of Auckland, Auckland, New Zealand. Mice were injected subcutaneously with 100 L of inoculate containing 2.5Â10 5 live EL -4 cells in phosphate -buffered saline ( PBS ), and tumor growth determined by measuring two perpendicular diameters. Animals were euthanised when tumors reached 1 cm in diameter, according to requirements of the University of Auckland Animal Ethics Committee. Cured animals were challenged 3 weeks after complete tumor rejection by intradermal injection of 2.5Â10 5 live EL -4 cells in the opposing flank, and followed for 3 months.
ADP affinity purification of hsps
Hsps were purified from EL -4 lymphomas using a procedure based on that previously published by Peng et al. 21 A collection of EL -4 tumors ( $20 g ) established in C57BL /6 mice was excised and homogenized on ice in 80 mL of ice -cold hypotonic buffer (10 mM NaHCO 3 , 0.5 mM PMSF, pH 7.1), supplemented with protease inhibitor ( Complete 2 ) tablets (Boehringer Mannheim, Mannheim, Germany ). The homogenate was centrifuged at 100,000Âg, and the supernatant applied directly to a 5-mL ADP agarose column (Sigma Chemical, St. Louis, MO ) equilibrated with buffer D ( 20 mM Tris -acetate, 20 mM NaCl, 15 mM -mercaptoethanol, 3 mM MgCl 2 , 0.5 mM PMSF, pH 7.5 ). The column was washed with buffer D containing 0.5 M NaCl, and then with buffer D alone. Finally, the column was incubated with buffer D containing 3 mM ADP ( Sigma ) for 30 minutes at room temperature, and hsps eluted with the same buffer were dialysed against PBS.
Vaccination with hsps and peptides
Hsps. Mice were subcutaneously injected, twice on alternate weeks, with 15 g of ADP agarose-purified hsps or PBS in 100 L volume. On the third week, mice were challenged by intradermal injection of 2.5Â10 5 live EL -4 cells.
Peptides. A helper peptide comprising the Th epitope HBVc 128 -140/ I-A b ( H -TPPAYRPPNAPIL -OH ) and an EL -4-specific peptide (H -AQHPNAELL -OH ) 22 were purchased from Mimotopes, Clayton, Victoria, Australia. Mice were subcutaneously injected with peptides ( 100 g /mouse ) emulsified in IFA on alternate weeks. They were challenged 1 week after the last injection by intradermal administration of 2.5Â10 5 live EL -4 cells.
Expression plasmids and in situ gene transfer
The pR68 /4.1 plasmid containing the full -length rat hsp70.1 gene has been described previously. 23 A 3.2-kb fragment of the rat hsp70.1 gene containing the entire coding region was liberated from pR68 /4.1 and ligated into the pcDNA3 expression plasmid (Invitrogen, Carlsbad, CA, USA ). Fulllength mouse B7.1 cDNA 24 provided by Dr. P. Linsley ( Bristol -Myers -Squibb, Seattle, WA ) was inserted into the pRCCMV expression plasmid ( Invitrogen ). Purified DNA constructs were diluted in 5% glucose and 0.01% Triton X -100, and mixed with DOTAP liposomes at the ratio of 1:3, as described previously. 20 The DNA -liposome transfection vehicle was directly injected into tumors in situ.
Immunohistochemistry
Tumor cryosections ( 8 m ) prepared 2 days following gene transfer were fixed in acetone, and blocked with mouse or rat sera. They were stained with a rat antimouse B7.1 mAb ( clone IG10; hybridoma obtained from the American Type Culture Collection ) and an anti -hsp70 mAb (clone BRM -22; Sigma ), which recognises both the constitutive and inducible forms of hsp70 from several species including rat, using the Vectastain Universal Quick kit ( Vector Laboratories, Burlingame, CA ). Immunoreactivity was developed with Sigma FAST DAB ( 3, 3 0 -diaminobenzidine tetrahydrochloride ) with CoCl 2 enhancer tablets (Sigma ).
Depletion of leukocyte subsets
Mice were depleted of leukocyte subsets by intraperitoneal and intravenous injection of mAbs (300 g ) against mouse CD8 ( clone 53-6.72 ), CD4 (clone Gk1.5 ), and NK cells ( clone PK136 ), purchased from the American Type Culture Collection, as described previously. 20 Antibodies were administered 4 days prior to injection of plasmids into tumors, and thereafter every alternate day for the 16 days tumor growth was monitored. A control group of mice was injected in the same manner with rat IgG (Sigma ).
Sodium dodecyl sulfate polyacrylamide gel electrophoresis ( SDS -PAGE ) and immunoblotting
The ADP affinity -purified hsp preparation and tumor homogenates were resolved by 10% SDS -PAGE. Proteins were transferred to nitrocellulose Hybond C membrane ( Amersham International, Buckingham, UK ) and probed with the anti -hsp70 mAb ( clone BRM -22 ).
RESULTS
An hsp preparation from EL -4 cells induces antitumor immunity
The first aim was to establish that an hsp preparation from EL -4 cells could induce antitumor immunity. Hsps were ADP affinity -purified from an EL -4 lymphoma homogenate, and analysed by SDS -PAGE (Fig 1A ) . A protein of 70 kDa, confirmed to be hsp70 by Western blot analysis, was the dominant protein isolated by ADP affinity chromatography. Two smaller unidentified proteins of 30-35 kDa were also present. To determine whether the hsp preparation was able to prophylactically protect against tumor challenge, mice were immunized twice on alternate weeks with 15 g of ADP affinity-purified protein. For comparison, mice were vaccinated with a combination of an EL -4 peptide ( AQHPNAELL ) and a Th epitope peptide (TPPAYRPPNA-PIL ), previously shown to induce antitumor immunity, 22 or injected with PBS. Vaccinated mice were challenged with 2.5Â10 5 live EL -4 cells 1 week following the last immunization. All immunised mice that had received either the hsp preparation, or the combination of tumor and Th epitope peptides, developed a tumor within 10 -15 days of challenge; however, tumor growth was significantly (P < .05) retarded compared to the unvaccinated control group ( Fig 1B ) .
Gene transfer of rat hsp70.1 into tumors in situ causes complete tumor regression by stimulating potent antitumor immunity
Given that an autologous hsp preparation from EL -4 cells could induce antitumor immunity, we examined whether gene therapy involving the direct transfer of an expression 1 ) that is detected by the anti -hsp70 mAb is not known, but may be degraded hsp70 that is not retained by ADP affinity chromatography. B: Generation of prophylactic antitumor immunity by vaccination with an EL -4 hsp preparation. Mice were vaccinated on alternate weeks by injection of the ADP affinitypurified hsp preparation ( 15 g; denoted hsps ), a combination of the EL -4 -specific peptide AQHPNAELL and a peptide containing a Th epitope ( 100 g each ), or PBS, followed by intradermal challenge with 2.5Â10 5 live EL -4 cells 1 week after the second immunization. Tumor growth was significantly ( P < .05 ) inhibited in mice immunized with either the hsps or the EL -4 -specific peptide. Each line represents the mean + SD tumor growth for five mice.
Cancer Gene Therapy, Vol 8, No 12, 2001 plasmid encoding rat hsp70.1 into tumors in situ could be used as a treatment strategy to eradicate established solid tumors, and generate systemic antitumor immunity. EL -4 tumors ( 0.2 cm in diameter ) were injected with a DNAliposome transfection vehicle containing 60 g of hsp70.1 -pcDNA3 DNA. As reported previously, direct injection of naked plasmids into tumors using a glucose -Triton X -100 -based DNA diluent provided excellent transfection efficiency, 20 reflected by good expression of the therapeutic gene in tumors as evidenced by expression of hsp70.1 in 90% of cells (Fig 2 ) . Complete tumor regression was observed within 10 days in five of six mice, and mice remained tumor-free for at least 20 days ( Fig 3) . In contrast, tumors injected with empty pcDNA3 plasmid continued to grow rapidly, reaching 0.8 cm in size within 20 days. Animals cured by hsp -mediated immunotherapy were challenged 3 weeks after complete tumor rejection with 2.5Â10 5 live EL -4 cells, and remained tumor-free for the 3 months they were monitored ( data not shown ).
Hsp70.1 -mediated gene therapy is dependent on gene dosage
We have previously demonstrated that antitumor immunity generated in response to B7.1 gene therapy is exquisitely dependent on gene dosage. 20 To establish the optimal gene dosage for hsp70.1, similar size tumors ( 0.2 cm in diameter ) were injected with either 30, 60, or 90 g of hsp70.1 -pcDNA3. Tumors were rapidly and completely eradicated from mice treated with 60 g of hsp70.1 expression plasmid, whereas lesser or greater amounts of plasmid were ineffective ( Fig 4 ) . As mentioned previously, gene transfer of 60 g of hsp70.1 expression plasmid led to expression of hsp70.1 in 90% of cells (Fig 2 ) .
Hsp70.1 -mediated antitumor immunity is dependent on CD4
+ and CD8 + T -cell subsets
In order to identify the immune cell subsets responsible for hsp70.1 -mediated antitumor immunity, mice were depleted of either CD8 + and CD4 + T cells, or NK cells prior to therapy. Antileukocyte subset blocking mAbs, or a control rat IgG antibody, was administered 4 days prior to gene transfer, and every alternate day for the 16 days tumor growth was monitored. The tumors of mice depleted of CD8 + and CD4 + T cells grew unchecked (P < .05), reaching 1 cm in diameter in 16 days (Fig 5 ) . In contrast, depletion of NK cells had only a small effect on abrogating tumor rejection.
B7.1 immunotherapy impairs the efficacy of hsp70.1 -mediated antitumor immunity
As reported previously, 20 gene transfer of mouse B7.1 into small (0.1 cm diameter ) tumors in situ can lead to complete tumor regression. In Figure 6A , tumors ( 0.2 cm in diameter ) 
RAFIEE, KANWAR, BERG, ET AL: CANCER IMMUNOTHERAPY BY GENE TRANSFER OF HSP70 IN SITU
were injected with a transfection vehicle containing 60 g B7.1-pRCCMV plasmid DNA. Complete tumor regression was observed in two mice within 12 days of gene transfer, whereas tumor growth was significantly (P < .05 ) retarded in the remaining four mice. To investigate whether coadministration of hsp70.1 and B7.1 leads to enhanced antitumor immunity, greater than that achieved with each monotherapy, EL -4 tumors (0.2 cm in diameter ) were simultaneously injected with 60 g each of the hsp70.1 -pcDNA3 and B7.1-pRCCMV plasmids. As shown in Figure 6B , complete tumor regression was observed in only one mouse, whereas tumor growth in another five mice was significantly ( P <.05 ) retarded for up to 6 days, after which growth continued unchecked. The timed delivery of hsp70.1, followed 2 days later by B7.1, resulted in greater retention of antitumor immunity in that although no mice showed complete tumor regression, tumor growth was significantly ( P <.001 ) retarded for 12 days following gene transfer ( Fig  6B ) . However, tumors began to rapidly regrow after day 12. In a separate experiment, timed delivery of hsp70.1 plasmid, followed 4 days later by B7.1 plasmid, also improved the outcome, but there was little further therapeutic benefit ( Fig  6C ) . In contrast, there was a significant (P < .001) therapeutic affect resulting in delayed tumor growth for 32 days when two injections of B7.1 plasmid were administered at 2 and 4 days following hsp70.1 gene transfer ( Fig 6C ) . However, a palpable tumor remained after therapy, and tumors began to regrow rapidly at day 32 following injection of the hsp70.1 and B7.1 plasmids. Contrary to expectations, . Following monotherapy with the B7.1 plasmid, complete tumor regression was observed in two ( denoted by dashed line ) of six mice, whereas tumor growth was significantly ( P < .05 ) retarded in the remaining four mice ( denoted by solid line ), compared to six control mice which received empty vector. B: Simultaneous transfer of 60 g of both hsp70.1 and B7.1 genes impaired hsp70.1 -mediated tumor rejection, as tumors grew unchecked in five of six mice ( ), where tumor growth was only slightly inhibited compared to mice whose tumors were injected with empty plasmid (^). Only one mouse ( denoted by dashed line ) was cured by this approach. A slight therapeutic benefit was retained by the timed delivery of hsp70.1, followed by B7.1 two days later, leading to significant ( P < .001 ) retardation of tumor growth for up to 12 days ( & ). Nevertheless, tumors began to rapidly regrow in all mice after day 14. C: A greater therapeutic benefit was obtained when two injections of B7.1 plasmid were administered at 2 and 4 days following hsp70.1 gene transfer, such that tumor growth was suppressed for 26 combined administration of hsp70.1 and B7.1 did not improve the therapeutic outcome above that achieved with hsp70.1 monotherapy.
DISCUSSION
In this report, we initially demonstrated that an hsp preparation derived from an EL -4 lymphoma exhibited antitumor activity, and could be employed to vaccinate mice against a challenge with live tumor cells. We did not attempt to separate the components of the preparation, the major proteins of which included hsp70 and unidentified proteins of 32 and 35 kDa. The hsp preparation was isolated from resected EL -4 tumors as we wanted the hsps to chaperone tumor antigens that would be present in the tumor in situ. However, it is interesting to note that hsp96 prepared from cultured Lewis lung carcinoma cells was as therapeutically active as hsp96 isolated from surgically resected solid tumor tissue. 9 A similar approach to the present study was undertaken by Graner et al 25 using chaperone -rich fractions prepared from A20 tumor lysates by a free solution /isoelectric focusing technique. Importantly, we could not detect any toxicity due to our hsp preparation, suggesting that ADP affinity chromatographypurified hsps could be administered as a prophylactic agent for patients who have undergone surgery to remove tumor growths. However, given that the hsps would be expected to complex with the repertoire of antigenic EL -4 tumor peptides, it came as a surprise that vaccination with the single EL -4 peptide AQHPNAELL in the presence of a Th epitope-containing peptide was just as effective as the hsp preparation at inducing an antitumor immune response. The AQHPNAELL H -2D b epitope mimic was first identified by searching combinatorial peptide libraries for epitopes recognized by H -2D b and K b -restricted CTL specific for the mouse lymphoma EL -4. 22 When injected into syngeneic mice, it elicited CTL that lysed EL -4 cells, and inhibited the growth of an EL -4 ascites tumor following adoptive transfer. These results serve to justify the effort being made in identifying tumor antigens recognized by antitumor CTL, the majority of which have turned out to be nonmutated self -antigens.
Since an hsp preparation from an EL -4 lymphoma was able to induce antitumor immunity, we then showed for the first time that gene transfer of mammalian hsp70 into tumors in situ could be used as a cancer treatment strategy. The success of in situ gene therapy with hsp70 for the treatment of solid tumors is in accord with the previous finding that intraperitoneal gene transfer of mycobacterial hsp65 leads to regression of highly malignant reticulum cell sarcomas. 17 In the latter experiment, it was argued that the ''foreignness'' of the 65-kDa mycobacterial antigen may contribute, at least in part, to its immunogenicity. Similarly, we have noted that gene transfer of xenogeneic forms of T-cell costimulators into tumors in situ can lead to enhanced antitumor immunity. 20 In the present study, a xenogeneic rat form of hsp70 was employed, which could similarly explain, in part, the potent antitumor activity achieved. However, rat hsp70.1 is near identical (98% amino acid identity ) to its mouse homologue. To our knowledge, the study by Rajdev et al 26 is the only other study where rat hsp70 has been introduced into mice, but this was in order to create a transgenic strain to examine the effects of overexpression of hsp70 on cerebral infarction. There were no untoward effects, suggesting that rat hsp70 is at least not toxic. Antitumor immunity is not simply a function of the antigenicity of the therapeutic protein introduced by gene transfer. We have found that introduction of a mutant nonfunctional form of human ICAM -1, which is much less homologous to mouse ICAM -1 than rat hsp70.1 is to mouse hsp70, into tumors only weakly inhibits tumor growth, whereas the functional form is a potent inducer of antitumor immunity and can completely eradicate tumors ( Kanwar et al, unpublished results ) . Thus, the foreignness of an antigen introduced into a tumor does not necessarily dictate whether effective systemic antitumor immunity capable of completely eradicating tumors will result. The introduced antigen appears to require some inherent function capable of specifically inducing systemic antitumor immunity.
The observed antitumor effect of hsp70.1 is due to the generation of antitumor systemic immunity, as mice cured by hsp70.1 monotherapy resisted a secondary challenge of nontransduced EL -4 cells injected 21 days following complete rejection of the primary tumor. However, we cannot exclude the possibility that there is also a bystander effect within the tumor as hsp70 is known to activate T cells and monocytes to produce proinflammatory cytokines, including TNF -.
12 Hsp70-mediated antitumor immunity was equally dependent on both CD4 + and CD8 + T cells, whereas NK cells did not appear to play a significant role. Conversely, tumor regression observed in SCID mice treated by mycobacterial hsp65 gene therapy suggested that T cellindependent mechanisms involving NK cells, macrophages, or changes in cell cycle regulation may contribute to antitumor immunity. 17 It has previously been shown that hsps may serve as targets for NK -mediated killing, 27 as does B7.1. 28 However, B16 cells stably transfected to express hsp70 did not display a markedly increased susceptibility to lysis by NK cells. 14 The antitumor immune response induced by hsp70.1 gene transfer is different from that elicited by costimulatory CAMs, which is mediated primarily by CD8 + T cells and NK cells, with negligible involvement of CD4 + T cells. 20 We found, as is the case for B7.1 immunotherapy, 20 that the efficacy of hsp70.1 -mediated antitumor immunity is exquisitely gene dosage -dependent. Gene transfer of 60 g of hsp70.1 was optimal in causing tumor regression, whereas greater or lesser amounts impaired antitumor immunity. This gene dosage effect may relate, at least in part, to transfection efficiency, as reported by Yang and Huang. 29 Using a chloramphenicol acetyltransferase ( CAT ) reporter gene, they established that plasmid transfection efficiency in situ was dose -dependent, such that highest CAT activity was obtained with 30-70 g of plasmid DNA. There may also be an effect of the amount of exogenous hsp70.1 expressed on therapeutic efficacy, as Graner et al 25 reported that increasing dosages of vaccines prepared from chaperone -rich fractions abrogated the protective effects of the vaccine. Contrary to our expectations, combined gene therapy with hsp70.1 to facilitate antigen presentation (signal 1), and B7.1 to costimulate T-cell proliferation (signal 2 ), led to a poorer outcome than that achieved by hsp70.1 -mediated monotherapy. A time delay in administering B7.1 following hsp70.1 gene transfer helped to lessen this problem, but nevertheless did not restore the potent antitumor effect observed with hsp70.1 monotherapy. There are potentially several plausible explanations as to why antitumor immunity was impaired. The lack of stimulation between hsp70 and B7.1 may relate to the requirements for T-cell costimulation. T-cell costimulation and antigen presentation are known to be dose -dependent. Thus, a strong signal 1 does not require signal 2, and in fact, inhibition of signal 2 in the presence of a strong signal 1 can actually enhance T-cell stimulation. 30 For signal 2 to be effective, it must be delivered in the presence of a weak signal 1. Thus, a strong signal 1 delivered by overexpression of hsp70 may actually be inhibited by costimulation via B7.1, which might explain, in part, the results obtained in the present study.
The potency of antitumor immunity achieved with hsp70.1 gene transfer presumably relates to the ability of hsp70 members to induce an infiltrate of T cells, macrophages, and DCs, as well as an intratumoral profile of protective Th1 cytokines. 15 As mentioned previously, both hsp70 and B7.1, in some instances, may render tumor cells more susceptible to lysis by NK cells, thereby initiating tumor cell death. Dying tumor cells would release tumor fragments, and hsp70 and its associated tumor peptides, with the latter being taken up directly into DCs. Hsp70 would chaperone tumor antigens for presentation, and thereby induce systemic antitumor immunity capable of killing both transduced and nontransduced cells within the tumor.
In summary, gene transfer of mammalian hsp70 into tumors in situ could provide an approach for the treatment of established tumors, with the ultimate aim of generating systemic antitumor immunity. Augmentation of this approach by harnessing other costimulatory pathways will require the careful consideration of the design of immunotherapy.
